Safety and efficacy of adding immunotherapy combined with stereotactic radiotherapy in patients with limited metastatic pancreatic cancer (MEPANC-1)

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 100

Inclusion Criteria

Histologically confirmed (metastatic) pancreatic cancer, as indicated by a definite cytology/histology report., Adequate liver tests (bilirubin < 1.5 times normal; ALAT/ASAT < 5 times normal)., Adequate bone marrow function (WBC > 3.0 x 109/L, platelets > 100 x 109/L and hemoglobin > 5.6 mmol/l)., Effective contraceptive methods., Written informed consent., Patients who did not complete at least 8 cycles of FOLFIRINOX due to severe toxicity, will be included in the expansion cohort., =5 hepatic and/or pulmonary metastases in total., The combined diameter of all liver metastases AND the primary tumour or local recurrence in the pancreas is <9 cm., The combined diameter of all pulmonary metastases is <9 cm., CA 19-9 < 1000 IU/mL after completion of chemotherapy., Age > 18 years and < 75 years., WHO performance status of 0-2., Tumour volume of the primary tumour <7cmx7cmx7cm. Each diameter must not exceed 7 cm., Adequate renal function (eGFR = 30 ml/min).

Exclusion Criteria

Metastasis in other organs than the lung and liver., Pregnancy, breast feeding., An active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or other immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment., Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the planned first dose of the study. The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor., History of Human Immunodeficiency Virus (HIV) (HIV-1/2 antibodies)., Active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected)., Positive PCR test for presence of SARS-CoV-2 during screening stage., Live virus vaccine within 30 days of planned start of trial treatment., Use of herbal remedies, including traditional Chinese herbal products (e.g., mistletoe)., Allergic reaction to M. obuense or had previously received IMM-101., Otherwise deemed unsuitable by the Investigator., Histopathologically proven extra regional lymph node metastasis., Malignant ascites., Liver function insufficient to tolerate the prescribed dose of radiotherapy. To be determined by the treating radiologist., Child-Pugh Classification grade B/C., Lung function insufficient to tolerate the prescribed dose of radiotherapy. To be determined by the treating radiologist., Diffuse liver metastasis pattern on CT scan., Current or previous treatment with immunotherapeutic drugs., Second primary malignancy except in situ carcinoma of the cervix, adequately treated non-melanoma skin cancer, or other malignancy treated at least 3 years previously to diagnosis of pancreatic cancer and without evidence of recurrence.

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials